Targeted Intervention for Bipolar Smokers

双相吸烟者的针对性干预

• 批准号: 8120403
• 负责人: Jaimee Heffner
• 金额: $ 13.53万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8120403
• 关键词: Abstinence; Adult; Affect; Area; Award; Behavior Therapy; Behavioral; Bipolar Disorder; Cessation Research; Cessation of life; Cigarette; Clinical Trials; Complex; Counseling; Disease; Exclusion; Expectancy; Feedback; Foundations; Funding; General Population; Goals; Health education; High Prevalence; Individual; Intervention; Manuals; Measures; Medicine; Mental disorders; Mentored Patient-Oriented Research Career Development Award; Mentors; Modeling; Nicotine Dependence; Outcome; Outcomes Research; Participant; Pharmacological Treatment; Phase; Pilot Projects; Plant Roots; Population; Randomized; Request for Proposals; Research; Research Infrastructure; Research Personnel; Research Support; Research Training; Resources; Role; Safety; Sampling; Smoke; Smoker; Smoking; Smoking Cessation Intervention; Solid; Staging; Substance Use Disorder; Symptoms; Testing; Therapeutic Studies; Time; Tobacco; Training; Training Programs; Treatment outcome; Universities; Withholding Treatment; base; biopsychosocial; career; career development; cigarette smoking; college; control trial; coping; dual diagnosis; efficacy trial; epidemiologic data; evidence base; experience; innovation; nicotine patch; nicotine replacement; novel; open label; pilot trial; programs; public health relevance; satisfaction; skills; smoking cessation; smoking prevalence; smoking relapse; social cognitive theory

DESCRIPTION (provided by applicant): The exclusion of individuals with bipolar disorder from smoking cessation treatment research to date is disconcerting, as the prevalence of smoking in this group is roughly double that of the general population and the efficacy and safety of current treatment approaches for bipolar smokers is essentially unknown. This K23 Mentored Patient-Oriented Research Career Development Award proposal requests a 5-year period of support for Dr. Jaimee Heffner to complete a focused program of training and research involving combined pharmacological and behavioral smoking cessation interventions for individuals with bipolar disorder. The proposed career development activities will facilitate Dr. Heffner's long-term career goal of identifying efficacious smoking cessation interventions for individuals with psychiatric disorders, with an emphasis on bipolar disorders and substance use disorders. Dr. Robert Anthenelli and Dr. Stephen Strakowski, the applicant's co-mentors and established investigators in the areas of smoking cessation and bipolar disorder treatment, respectively, will oversee completion of the applicant's career development goals. The University of Cincinnati College of Medicine will provide a strong infrastructure to complete both the training and research plans of the award. The proposed research plan includes developing and pilot testing a novel behavioral smoking cessation intervention, the Targeted Intervention for Bipolar Smokers (TIBS). TIBS will be developed and pilot-tested in two phases, consistent with Stage Ia and Stage Ib of the Stage Model of Behavioral Therapies research (Rounsaville, Carroll, & Onken, 2001). The first phase will involve developing a treatment manual, treatment integrity measures, and therapist training materials, as well as pre-pilot testing (n=10). The second phase will be a 12-week pilot trial in which all participants will be randomized to receive either TIBS (n=20) or a control treatment equated for contact time (n=20). All participants will receive 8 weeks of open- label transdermal nicotine replacement therapy. The results of this research will lay the groundwork for an R01 application to fund a larger-scale efficacy trial as well as advancing understanding of the complex relationship between psychiatric symptoms and smoking. PUBLIC HEALTH RELEVANCE: Individuals with psychiatric disorders smoke almost half of the cigarettes sold in the U.S. and die up to three decades earlier than individuals who do not have psychiatric disorders. This award will allow the applicant to develop expertise in smoking cessation research for individuals with bipolar disorder, a critically underserved group with a high prevalence of smoking and low rate of successful quitting.

描述(由申请人提供)：迄今为止，将双相情感障碍患者排除在戒烟治疗研究之外的情况令人不安，因为这一群体的吸烟率大约是普通人群的两倍，目前对双相情感吸烟者的治疗方法的有效性和安全性基本上是未知的。这项K23指导的以患者为导向的研究职业发展奖提案要求为Jaimee Heffner博士提供为期5年的支持，以完成针对双相情感障碍患者的重点培训和研究计划，包括药物和行为戒烟干预。拟议的职业发展活动将促进赫夫纳博士的长期职业目标，即为患有精神障碍的个人确定有效的戒烟干预措施，重点是双相情感障碍和药物使用障碍。罗伯特·安东内利博士和斯蒂芬·斯特拉科夫斯基博士分别是申请者在戒烟和躁郁症治疗领域的共同导师和资深调查人员，他们将监督申请者职业发展目标的完成。辛辛那提大学医学院将提供强大的基础设施，以完成该奖项的培训和研究计划。拟议的研究计划包括开发和试点测试一种新型的行为戒烟干预措施，即针对双相吸烟者的靶向干预(TIBS)。TIB将分两个阶段进行开发和试点测试，这与行为疗法研究阶段模型(Rounaville，Carroll和Onken，2001)的阶段Ia和阶段Ib一致。第一阶段将包括编写治疗手册、治疗完整性措施、治疗师培训材料以及试点前测试(n=10)。第二阶段将是为期12周的试点试验，所有参与者将随机接受TIBS(n=20)或接触时间相等的对照治疗(n=20)。所有参与者都将接受为期8周的开放式经皮尼古丁替代疗法。这项研究的结果将为R01的应用奠定基础，以资助更大规模的疗效试验，并促进对精神症状和吸烟之间复杂关系的理解。 与公共健康相关：患有精神障碍的人吸烟的香烟几乎占美国销售的香烟总数的一半，而且比没有精神障碍的人早死长达30年。该奖项将允许申请者为双相情感障碍患者发展戒烟研究方面的专业知识，双相情感障碍患者是一个严重缺乏服务的群体，吸烟率高，戒烟成功率低。